Research across Cancer
Related studies from across the Cancer family.
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
Network meta-analysis reveals induction immunochemotherapy plus CCRT improves survival for unresectable esophageal cancer patients compared to CCRT alone
Immunotherapy combinations show promise for hard-to-treat esophageal cancer
A comprehensive network meta-analysis of 9,648 patients indicates that induction immunochemotherapy followed by concurrent chemoradiotherapy…
Adding immunotherapy to standard treatment may help people with advanced esophageal cancer live longer, according to a new analysis of many …
Meta-analysis shows neoadjuvant chemoradiation improves resection and survival outcomes for esophageal squamous cell carcinoma patients compared to chemotherapy alone
Adding radiation before surgery helps some esophageal cancer patients get better surgery results and live longer
This meta-analysis of 2,174 patients reveals that adding radiation to chemotherapy significantly boosts resection rates and survival for squ…
A large review found that adding radiation to chemotherapy before surgery helped remove more tumors in certain cancer types. This approach a…
Disease progression and death in a 10 year old male with lower esophageal squamous cell carcinoma
Rare case: child dies 7 months after esophageal cancer diagnosis
This case report and retrospective literature analysis describes a 10 year old male with lower esophageal squamous cell carcinoma.
A 10-year-old with a rare esophageal cancer died 7 months after diagnosis, highlighting the urgent need for better treatments.
Retrospective review finds higher ORR with salvage DCRT in locally advanced ESCC
Salvage therapy works better than upfront treatment for some esophageal cancer patients
This retrospective analysis of 91 patients from 3 medical centers compared salvage versus upfront definitive chemoradiotherapy (DCRT) for lo…
New data shows treating esophageal cancer after a failed first attempt may lead to better outcomes than starting with the strongest drugs im…
Combining chemotherapy, immunotherapy, and high-dose radiation achieved remission in a patient with cervical esophageal adenocarcinoma
Rare throat cancer vanishes after bold three-pronged treatment
This case report describes a 39-year-old male with cervical esophageal adenocarcinoma treated with standard chemotherapy and immunotherapy c…
A 39-year-old man with rare throat cancer reached complete remission after doctors combined chemo, immunotherapy, and high-dose radiation.
Meta-analysis finds TSP-9 test predicts progression to HGD/EAC in Barrett's esophagus
TSP-9 test predicts disease progression in Barrett's esophagus patients with high accuracy
A systematic review and meta-analysis of 699 patients with Barrett's esophagus found the Tissue Systems Pathology (TSP-9) test was associate…
A new test for Barrett's esophagus accurately predicts who is at high risk of developing serious esophageal cancer, helping doctors focus ca…
pCR shows poor surrogacy for OS in neoadjuvant GEA trials overall, but strong for esophageal adenocarcinoma
When a cancer disappears before surgery, does it mean patients live longer? Not always, a major review finds
A meta-analysis of 26 RCTs (n=7452) found pathologic complete response (pCR) was not a valid surrogate for overall survival (OS) in neoadjuv…
For stomach or esophageal cancer, a tumor disappearing before surgery does not always mean patients live longer, a major review finds.